As the COVID-19 pandemic continues and the number of individuals with previous infection rises, numbers of SARS-CoV-2 reinfection are increasing. The second Omicron wave in Shanghai, China caused by BA.5-sublineages led to a large fraction of reinfections among BA.2 primary infections. To better understand the SARS-CoV-2 reinfection rate and clinical severity of reinfections, the investigators conducted a multi-centre cohort study. The investigators hope to provide valuable clinical evidences for reinfections and offer guidance for future policy making.
The investigators used data from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital to collect information on SARS-CoV-2 primary infections with BA.2 during 1 March to 23 May 2022, and followed up for participants' reinfections with BA.5-lineages during 1 December 2022 to 14 January 2023. After matched 1:1 by age and gender with the reinfection cohort, data of primary infections with BA.5-sublineages were also collected. Reinfection cases were defined as having positive COVID-19 PCR or antigen test, at least 90 days after participants' first positive testing. Basic information, vaccination status, time interval between two infections, and clinical manifestations were collected.
Study Type
OBSERVATIONAL
Enrollment
1,144
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Characteristics of all enrolled SARS-CoV-2 patients during two periods.
Basic information, vaccination status, time interval between two infections, and clinical manifestations
Time frame: 2022-12~2023-2
Characteristics and multivariate analysis of risk factors for SARS-CoV-2 reinfection by gender, age, vaccination status, clinical severity and Ct values of primary infection.
Sex, age, vaccination status, clinical severity of primary infection, and Ct values during primary infection
Time frame: 2022-12~2023-2
Clinical characteristics of SARS-CoV-2 primary infection and reinfection among patients with reinfection in Shanghai
Fever, fatigue, sore throat, cough, anosmia and/or ageusia, muscle and/or joint pain, headache, chest congestion, diarrhea, runny nose, sleeping disorders, and pneumonia
Time frame: 2022-12~2023-2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.